GSK/Sierra24 May 2022 20:56
As Basser1 has posted on several occasions, GSK offer does seem ridiculously undervalued on the basis that not only what Sierra have already developed but importantantly with SRA737 bubbling away in the background. With the astute Pharmas hovering in the background that surely are aware of 737 potential I feel an improved offer/offers from other majors might not be far away.
GLA